AlanJKivitzMD

Rheumatology • Duncansville, PA

Physician

Join to view full profile

Dr. Kivitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kivitz's full profile

Already have an account?

Office
175 Meadowbrook Lane
Duncansville, PA 16635
Phone+1 814-693-0300

Fax+1 814-693-0400
Is this information wrong?

Education & Training

Albany Medical CenterFellowship, Rheumatology, 1980 - 1982
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1977 - 1979
Albany Medical CollegeClass of 1977

Certifications & Licensure

PA State Medical License 1982 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2006
Fellow (FACR) American College of Rheumatology

Clinical Trials

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis Start of enrollment: 2005 Dec 01
Terminated
Phase 2
Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee Start of enrollment: 2006 Apr 01
Completed
Not Applicable
Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome Start of enrollment: 2008 Feb 01
Completed
Phase 2
Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers Start of enrollment: 2009 Jan 01
Completed
Phase 1, Phase 2
Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee Start of enrollment: 2006 Mar 01
Completed
Not Applicable
Safety and Efficacy Study of Intravenous Uricase-PEG 20 Start of enrollment: 2009 Oct 01
Unknown status
Phase 1
Safety and Efficacy Study of Intramuscular Uricase-PEG 20 Start of enrollment: 2009 Dec 01
Unknown status
Phase 1
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome Start of enrollment: 2011 Mar 01
Completed
Phase 3
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects Start of enrollment: 2013 May 01
Completed
Phase 1
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Start of enrollment: 2012 Apr 01
Completed
Phase 4
Study of Meloxicam Capsules to Treat Osteoarthritis Pain Start of enrollment: 2013 Feb 01
Completed
Phase 3
Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. Start of enrollment: 2013 Jul 01
Completed
Phase 1, Phase 2
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2013 Jun 27
Completed
Phase 3
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Start of enrollment: 2014 Jan 01
Terminated
Phase 3
A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Start of enrollment: 2014 Feb 01
Completed
Phase 2
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) Start of enrollment: 2014 May 01
Completed
Phase 3
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Start of enrollment: 2014 Jun 16
Completed
Phase 3
A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain Start of enrollment: 2014 Jul 01
Terminated
Phase 2
A Study of LY3337641 in Rheumatoid Arthritis Start of enrollment: 2016 Aug 22
Terminated
Phase 2
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon Start of enrollment: 2016 Feb 01
Completed
Not Applicable
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 12
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.
Clarence W Legerton 3rd, Luminita Pricop, Alan J Kivitz, Joel M Kremer, Atul Singhal> ;Rheumatology and Therapy. 2024 Apr 16
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELE...
Gerd R Burmester, Filip Van den Bosch, Yanxi Liu, Nasser Khan, Heidi S Camp, John Tesser, Anna Shmagel, Alan Kivitz> ;The Journal of Rheumatology. 2024 Apr 15
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M C...> ;Rheumatology and Therapy. 2024 Mar 18
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
Sławomir Jeka, Eva Dokoupilová, Alan Kivitz, Paweł Żuchowski, Barbara Vogg, Natalia Krivtsova, Susmit Sekhar, Samik Banerjee, Arnd Schwebig, Johann Poetzl, Jean-Jacque...> ;Journal of Bone and Mineral Research. 2024 Jan 29
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observa...
Anisha B Dua, Kerri Ford, Stefano Fiore, Dimitrios A Pappas, Jud C Janak, Taylor Blachley, Carla Roberts-Toler, Kelechi Emeanuru, Joel M Kremer, Alan Kivitz> ;Rheumatology and Therapy. 2023 Dec 1
1 citations
The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep...
Alan Kivitz, Liangwei Wang, Ilias Alevizos, Michele Gunsior, Judith Falloon, Gabor Illei, E William St Clair> ;RMD Open. 2023 Aug 1
3 citations
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
Herbert S B Baraf, Puja P Khanna, Alan J Kivitz, Vibeke Strand, Hyon K Choi, Robert Terkeltaub, Nicola Dalbeth, Wesley DeHaan, Rehan Azeem, Peter G Traber, Robert T Ke...> ;Rheumatology. 2024 Apr 2
6 citations
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.
Matthew C Baker, Sarah Kavanagh, Stanley Cohen, Alan K Matsumoto, Ara Dikranian, John Tesser, Alan Kivitz, Konstantinos Alataris, Mark C Genovese> ;Arthritis & Rheumatology. 2023 Dec 1
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study.
Alan Kivitz, Alvin F Wells, Juan I Vargas, Herbert S B Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez> ;Rheumatology and Therapy. 2023 Aug 1
18 citations
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.
Jay Tuttle, Edit Drescher, Jesus Abraham Simón-Campos, Paul Emery, Maria Greenwald, Alan Kivitz, Hyungmin Rha, Pia Yachi, Christina Kiley, Ajay Nirula> ;The New England Journal of Medicine. 2023 May 18
8 citations
Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110).
Alan Kivitz, Wesley DeHaan, Justin Park, Sheri Rhodes, Jamie Inshaw, Sheldon S Leung, Savvas Nicolaou, Lloyd Johnston, Takashi K Kishimoto, Peter G Traber, Earl Sands,...> ;Rheumatology and Therapy. 2023 Aug 1
Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional...
Aaron Broadwell, Joy Schechtman, Douglas Conaway, Alan Kivitz, Natalie J Shiff, Shawn Black, Stephen Xu, Wayne Langholff, Sergio Schwartzman, Jeffrey R Curtis> ;BMC Rheumatology. 2023 Mar 27
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
Gerd R Burmester, Vibeke Strand, Alan J Kivitz, Chih-Chi Hu, Sheldon Wang, Hubert van Hoogstraten, Gabriella L Klier, Roy Fleischmann> ;Rheumatology. 2023 Oct 3
2 citations
Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis.
David Gordon, Alan Kivitz, Atul Singhal, David Burt, Madison C Bangs, Emma E Huff, Heidi Rath Hope, Joseph B Monahan> ;ACR Open Rheumatology. 2023 Feb 1
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 St...
Bernard G Combe, Yoshiya Tanaka, Maya H Buch, Peter Nash, Gerd R Burmester, Alan J Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Th...> ;Rheumatology and Therapy. 2023 Feb 1
1 citations
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Naoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Eiji Sugiyama, Kunihiro Yamaoka, Kevin Winthrop, Alan Kivitz, Gerd R Burmester, Jacque...> ;Modern Rheumatology. 2023 Jan 3
Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study i...
Alan Kivitz, Alicia M Ellis, Vishvesh Shende, Jérémy Lambert, Daljit Tatla> ;Patient Preference and Adherence. 2023 Jan 1
8 citations
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Byron Padilla, Alan Ki...> ;Rheumatology. 2023 Jun 1
3 citations
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Bernard G Combe, Yoshiya Tanaka, Maya H Buch, Peter Nash, Gerd R Burmester, Alan J Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Th...> ;Rheumatology and Therapy. 2023 Feb 1
4 citations
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
Philip J Mease, Herbert Kellner, Akimichi Morita, Alan J Kivitz, Stella Aslanyan, Steven J Padula, Andrew S Topp, Ann Eldred, Frank Behrens, Kim A Papp> ;Rheumatology and Therapy. 2022 Oct 1
1 citations
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edwar...> ;Modern Rheumatology. 2023 Jul 4
3 citations
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Ar...
Lubna Abuqayyas, Laurence E Cheng, Marcia Teixeira Dos Santos, Barbara A Sullivan, Norma Ruiz-Santiago, Hui Wang, Yanchen Zhou, Vishala Chindalore, Stanley Cohen, Alan...> ;ACR Open Rheumatology. 2022 Oct 1
6 citations
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label E...
Xenofon Baraliakos, Atul Deodhar, Maxime Dougados, Lianne S Gensler, Anna Molto, Sofia Ramiro, Alan J Kivitz, Denis Poddubnyy, Marga Oortgiesen, Thomas Vaux, Carmen Fl...> ;Arthritis & Rheumatology. 2022 Dec 1
75 citations
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Philip J Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee> ;Annals of the Rheumatic Diseases. 2022 Jun 1
4 citations
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2.
Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, Byron Padilla, Zailong Wang, Ann Eldred, Kurt de Vlam, Alan Kivitz> ;RMD Open. 2022 Jun 1
Join now to see all

Journal Articles

Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch from Reference Rituximab in Patients with Active Rheumatoid Arthritis
Alan Kivitz, MD, Arthritis Care & Research

Authored Content

Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialOctober 2020

Press Mentions

Pfizer, French Business Begins Trials of Key Lyme Disease VaccineAugust 9th, 2022
Clinical Trial Aims to Develop 1st Lyme Disease Vaccine in 20 YearsAugust 8th, 2022
Pfizer Begins Late-Stage Trial Testing Lyme Disease VaccineAugust 8th, 2022
Join now to see all